Monday, December 19, 2005 8:38:49 AM ET
Dow Jones Newswires

1229 GMT [Dow Jones] Elan -4.2% at EUR11.20 in profit-taking after a 30%-plus gain since the start of December, says Goodbody Stockbrokers' Ian Hunter. The FDA Advisory Committee for peripheral and central nervous system drugs will possibly review MS drug Tysabri on March 7 and 8, according to Elan's partner on Tysabri. Hunter says momentum in Elan could ease over the holidays. Maintains buy. (QAF)

Contact us in London.
+44-20-7842-9464
Markettalk.eu@dowjones.com

Copyright (c) 2005 Dow Jones & Company, Inc.

Elan Corporation | detailed quote - chart - all headlines

previous | next

12/19/05	Elan "buy"	Goodbody Stockbrokers
12/08/05	Elan +6% As Tysabri Hopes Continue
11/18/05	NCB Sees Elan's Tysabri Hitting $1B Sales

http://www.newratings.com/analyst_news/article_1163515.html